Brugia

Brugia is a genus of parasitic nematode worms that belong to the family Filariidae. They are known to cause a disease known as lymphatic filariasis in humans, which is a major public health concern in many tropical and subtropical regions of the world. The two most common species that infect humans are Brugia malayi and Brugia timori.

Life Cycle

The life cycle of Brugia involves two hosts: a definitive host (humans) and an intermediate host (mosquitoes). The adult worms live in the lymphatic system of the human host, where they produce microfilariae. These microfilariae circulate in the peripheral blood and are ingested by a mosquito during a blood meal. Inside the mosquito, the microfilariae develop into infective larvae, which are then transmitted to a new human host when the mosquito takes another blood meal.

Disease

Infection with Brugia can lead to a disease known as lymphatic filariasis, which is characterized by chronic lymphedema, elephantiasis, and hydrocele. The disease is often debilitating and can significantly impact the quality of life of those affected.

Diagnosis and Treatment

Diagnosis of Brugia infection is typically made by identifying microfilariae in a blood smear. Treatment involves the use of antiparasitic drugs, such as diethylcarbamazine and ivermectin. In some cases, surgical intervention may be necessary to manage the complications of the disease.

Prevention and Control

Prevention and control of Brugia infection primarily involves vector control strategies, such as the use of insecticide-treated bed nets and indoor residual spraying. Mass drug administration programs are also implemented in endemic areas to reduce the prevalence of the disease.

See Also

• Lymphatic filariasis
• Parasitic worms
• Tropical diseases

References

Brugia Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.